With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.109384-27-2,1-Methylpiperazin-2-one hydrochloride,as a common compound, the synthetic route is as follows.
(rac)-6-chloro-3-(1 -(4,6-difluoro-1 -isopropyl-1 H-indazol-5-yl)ethyl)imidazo[1 ,2-b]pyridazine (Intermediate U, 56.4 mg, 0.15 mmol), KF (43.6 mg, 0.75 mmol) and 1-methylperazine-2- one hydrochloride (51.4 mg, 0.45 mmol) were suspended in NMP (0.4 ml_). The RM was stirred at 180 0C for 4 h. The mixture was diluted with EtOAc and washed with NaHCO3 10% (2 x) and water (4 x). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography and afforded the title compound as a light brown foam (tR 4.06 min (conditions 5), MH+ = 454.3, 1H-NMR in DMS0-d6: 8.09 (s, 1 H); 7.81 (d, 1 H); 7.53 (s, 1 H); 7.43 (d, 1H); 7.05 (d, 1 H), 4.86 (m, 2H); 4.03 (d, 1H); 3.81 (d, 1H); 3.64 (m, 2H); 3.24 (m, 2H); 2.80 (s, 3H); 1.79 (d, 3H), 1.41 (m, 6H)).
109384-27-2, The synthetic route of 109384-27-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; NOVARTIS AG; FURET, Pascal; McCARTHY, Clive; SCHOEPFER, Joseph; STUTZ, Stefan; WO2011/15652; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics